ENTERA BIO LTD. Deferred Income Tax Assets, Net
ENTERA BIO LTD. (ENTX) had Deferred Income Tax Assets, Net of $0 as of 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2025-03-28
- 2024-12-31: Deferred Income Tax Assets, Net $0.00.
- 2024-09-30: Deferred Income Tax Assets, Net $14.00K.
- 2024-06-30: Deferred Income Tax Assets, Net $14.00K.
- 2024-03-31: Deferred Income Tax Assets, Net $14.00K.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-28 |
| 2024-09-30 | $14.00K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $14.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $14.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $14.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $15.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $43.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $43.00K 10-Q · filed 2023-05-05 |
| 2022-12-31 | $43.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $66.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $280.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $250.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $217.00K 10-K · filed 2023-03-31 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |